Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 79

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 2
Chunk 79
---
.3 million of other income consisting of interest income partially offset by interest expense.

Liquidity and Capital Resources 

Liquidity
is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate
on an ongoing basis.

We incurred a net loss of
$40.7 million and $32.9 million for the nine months ended September 30, 2025 and 2024, respectively. Net cash used in operating activities
was $19.6 million and $22.3 million for the nine months ended September 30, 2025 and 2024, respectively. Since inception, we have funded
our operations primarily with proceeds from the sales of our common stock. As of September 30, 2025, we had cash and cash equivalents
of $27.7 million. We anticipate that operating losses and net cash used in operating activities will increase over the next few years
as we advance our products under development.

During the nine months ending
September 30, 2025, the Company sold 1,304,707 shares of common stock at an average price of $8.01 for gross proceeds of approximately
$10.4 million under the ATM offering.

During June 2025, the Company
entered into securities purchase agreements with investors whereby the Company sold 3,000,000 shares of the common stock in a registered
direct offering in exchange for gross proceeds of $18.9 million (net proceeds of approximately $17.4 million).

Our
primary uses of capital are, and we expect will continue to be, third-party clinical and preclinical research and development services,
costs incurred to manufacture our drugs under development, compensation and related expenses, legal, patent and other regulatory expenses
and general overhead costs. We believe our use of CROs provides us with flexibility in managing our spending.

The
Company incurs significant research and development expenses in Australia and the United Kingdom. Fluctuations in the rate of exchange
between the United States dollar and the pound sterling as well as the Australian dollar could adversely affect our financial results,
including our expenses as well as assets and liabilities. We currently do not hedge foreign currencies but will continue to assess whether
that strategy is appropriate. As of September 30, 2025, the cash balance held by our foreign subsidiaries with currencies other than the
United States dollar was approximately $0.2 million.

Our
recurring net losses and negative cash flows from operations